Australia markets closed

Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
208.81-4.32 (-2.03%)
As of 02:20PM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 128.58B
Enterprise value 127.48B
Trailing P/E 42.80
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)12.12
Price/book (mrq)8.97
Enterprise value/revenue 12.03
Enterprise value/EBITDA 35.06

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-25.49%
S&P500 52-week change 324.43%
52-week high 3298.50
52-week low 3180.69
50-day moving average 3229.91
200-day moving average 3237.38

Share statistics

Avg vol (3-month) 31.69M
Avg vol (10-day) 31.83M
Shares outstanding 5603.32M
Implied shares outstanding 6611.74M
Float 8231.15M
% held by insiders 161.69%
% held by institutions 16.91%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 42.32
Forward annual dividend yield 41.09%
Trailing annual dividend rate 32.32
Trailing annual dividend yield 31.09%
5-year average dividend yield 40.40
Payout ratio 425.10%
Dividend date 3N/A
Ex-dividend date 407 June 2024
Last split factor 215:10
Last split date 324 May 2016

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 28.32%
Operating margin (ttm)36.25%

Management effectiveness

Return on assets (ttm)12.98%
Return on equity (ttm)22.17%

Income statement

Revenue (ttm)10.6B
Revenue per share (ttm)17.58
Quarterly revenue growth (yoy)20.60%
Gross profit (ttm)N/A
EBITDA 3.54B
Net income avi to common (ttm)3B
Diluted EPS (ttm)4.99
Quarterly earnings growth (yoy)26.60%

Balance sheet

Total cash (mrq)2.37B
Total cash per share (mrq)3.94
Total debt (mrq)1.27B
Total debt/equity (mrq)8.54%
Current ratio (mrq)5.27
Book value per share (mrq)23.76

Cash flow statement

Operating cash flow (ttm)2.1B
Levered free cash flow (ttm)-890.19M